Dr Imran Haque, SVP of AI and Digital Sciences at Recursion Pharmaceuticals, discusses why AI drug discovery is challenging, the need for better understanding of drug interactions, the trade-offs in translational models, advancements in computational modeling and data acquisition in biology, and the value of being a generalist in the field.